33.13
1.06 (3.31%)
| Previous Close | 32.07 |
| Open | 32.11 |
| Volume | 65,290 |
| Avg. Volume (3M) | 146,109 |
| Market Cap | 515,503,520 |
| Price / Sales | 8.80 |
| Price / Book | 3.29 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -124.15% |
| Operating Margin (TTM) | -105.54% |
| Diluted EPS (TTM) | -6.20 |
| Quarterly Revenue Growth (YOY) | 62.80% |
| Total Debt/Equity (MRQ) | 11.13% |
| Current Ratio (MRQ) | 2.05 |
| Operating Cash Flow (TTM) | -56.19 M |
| Levered Free Cash Flow (TTM) | -16.50 M |
| Return on Assets (TTM) | -25.49% |
| Return on Equity (TTM) | -133.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Assembly Biosciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
|
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 39.25% |
| % Held by Institutions | 12.77% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| B Group, Inc. | 30 Jun 2025 | 189,350 |
| Monimus Capital Management, Lp | 30 Jun 2025 | 42,067 |
| Palumbo Wealth Management Llc | 30 Sep 2025 | 34,798 |
| Ellsworth Advisors, Llc | 30 Sep 2025 | 29,950 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (HC Wainwright & Co., 50.92%) | Buy |
| Median | 39.50 (19.23%) | |
| Low | 38.00 (JMP Securities, 14.70%) | Buy |
| Average | 41.75 (26.02%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 28.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 20 Nov 2025 | 40.00 (20.74%) | Buy | 36.73 |
| HC Wainwright & Co. | 14 Oct 2025 | 50.00 (50.92%) | Buy | 28.39 |
| JMP Securities | 24 Sep 2025 | 38.00 (14.70%) | Buy | 25.66 |
| Guggenheim | 08 Sep 2025 | 39.00 (17.72%) | Buy | 23.32 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |